Literature DB >> 26891251

Multitarget Drugs: an Epigenetic Epiphany.

A Ganesan1.   

Abstract

Epigenetics refers to changes in a biological phenotype that are not due to an underlying change in genotype. In eukaryotes, epigenetics involves a set of chemical modifications of the DNA and the histone proteins in nucleosomes. These dynamic changes are carried out by enzymes and modulate protein-protein and protein-nucleic acid interactions to determine whether specific genes are expressed or silenced. Both the epigenetic enzymes and recognition domains are currently important drug discovery targets, particularly for the treatment of cancer. This review summarizes the progress of epigenetic targets that have reached a clinical stage: DNA methyltransferases, histone deacetylases, lysine methyltransferases, lysine demethylases, and bromodomains; this is followed by a comprehensive survey of multitarget drugs that have included an epigenetic target as one of their mechanisms of action.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer; dual inhibitors; epigenetics; histone deacetylases; multitarget drugs

Mesh:

Substances:

Year:  2016        PMID: 26891251     DOI: 10.1002/cmdc.201500394

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  19 in total

1.  The relevance of Ki calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor.

Authors:  Hannah Wapenaar; Thea van den Bosch; Niek G J Leus; Petra E van der Wouden; Nikolaos Eleftheriadis; Jos Hermans; Gebremedhin Solomon Hailu; Dante Rotili; Antonello Mai; Alexander Dömling; Rainer Bischoff; Hidde J Haisma; Frank J Dekker
Journal:  Eur J Med Chem       Date:  2017-05-05       Impact factor: 6.514

2.  Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.

Authors:  Sanil Bhatia; Viktoria Krieger; Michael Groll; Jeremy D Osko; Nina Reßing; Heinz Ahlert; Arndt Borkhardt; Thomas Kurz; David W Christianson; Julia Hauer; Finn K Hansen
Journal:  J Med Chem       Date:  2018-11-08       Impact factor: 7.446

3.  Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.

Authors:  Beth E Zucconi; Jessica L Makofske; David J Meyers; Yousang Hwang; Mingxuan Wu; Mitzi I Kuroda; Philip A Cole
Journal:  Biochemistry       Date:  2019-04-11       Impact factor: 3.162

Review 4.  Epigenetic drug discovery: a success story for cofactor interference.

Authors:  A Ganesan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

5.  Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.

Authors:  Kun Fang; Guoqiang Dong; Yu Li; Shipeng He; Ying Wu; Shanchao Wu; Wei Wang; Chunquan Sheng
Journal:  ACS Med Chem Lett       Date:  2018-03-26       Impact factor: 4.345

Review 6.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944

Review 7.  Histone lysine specific demethylase 1 inhibitors.

Authors:  Samir Mehndiratta; Jing-Ping Liou
Journal:  RSC Med Chem       Date:  2020-07-31

Review 8.  Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex.

Authors:  Omeima Abdullah; Ziad Omran; Salman Hosawi; Ali Hamiche; Christian Bronner; Mahmoud Alhosin
Journal:  Genes (Basel)       Date:  2021-04-22       Impact factor: 4.096

Review 9.  Epigenetic polypharmacology: from combination therapy to multitargeted drugs.

Authors:  Angel R de Lera; A Ganesan
Journal:  Clin Epigenetics       Date:  2016-10-12       Impact factor: 6.551

Review 10.  Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer's disease: looking in the correct place at the right time?

Authors:  A Iatrou; G Kenis; B P F Rutten; K Lunnon; D L A van den Hove
Journal:  Cell Mol Life Sci       Date:  2016-09-14       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.